We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Xultophy

News List

Positive results for Novo’s Xultophy pharmatimes
June 11, 2019
“In clinical practice this becomes relevant as the longer a patient can remain in good control, the less exposure there is to high blood sugar, and the fewer escalations, or changes, in therapy are required.”
Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for Peop prnasia
December 12, 2017
Regardless of which treatment the study participants were switched from, the average decrease in blood sugar was significant.[1]
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies pharmafile
December 06, 2017
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and Tresiba, demonstrating the benefits they can provide to patients.
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies pharmafile
December 06, 2017
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and Tresiba, demonstrating the benefits they can provide to patients.